| US 7,414,049 B2 | ||
| 4-oxo-2,3,4,5-tetrahydro-benzo[b][1,4]diazepine derivatives | ||
| Alexander Flohr, Reinach BL (Switzerland); Roland Jakob-Roetne, Inzlingen (Germany); and Wolfgang Wostl, Grenzach-Wyhlen (Germany) | ||
| Assigned to Hoffmann-La Roche Inc., Nutley, N.J. (US) | ||
| Filed on Sep. 14, 2007, as Appl. No. 11/855,262. | ||
| Claims priority of application No. 06120956 (EP), filed on Sep. 20, 2006. | ||
| Prior Publication US 2008/0103133 A1, May 01, 2008 | ||
| Int. Cl. A61K 31/5513 (2006.01); C07D 243/12 (2006.01) | ||
| U.S. Cl. 514—221 [540/517] | 8 Claims |
1. A compound of formula I
 R1 is hydrogen, lower alkyl substituted by halogen or lower alkyl substituted by hydroxy;
R2 is lower alkyl substituted by halogen or lower alkyl substituted by hydroxy, or is —COO(CH2)nR5;
n is 1, 2, or 3;
R5 is hydroxy for n=2 or 3 or is lower alkyl substituted by halogen for n=1, 2 or 3; and
R3 and R4 are each independently hydrogen or halogen;
or a pharmaceutically suitable acid addition salt, optically pure enantiomer, racemate or diastereomeric mixture thereof.
|